GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Total Payout Ratio

CTOR (Citius Oncology) Total Payout Ratio : 0.00 (As of May. 02, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Citius Oncology's current Total Payout Ratio is 0.00.

Citius Oncology Total Payout Ratio Historical Data

The historical data trend for Citius Oncology's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Total Payout Ratio Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Total Payout Ratio
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Total Payout Ratio - - -

Competitive Comparison of Citius Oncology's Total Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Total Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Total Payout Ratio falls into.


;
;

Citius Oncology Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Citius Oncology's Total Payout Ratio for the fiscal year that ended in Sep. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -21.149
=0.00

Citius Oncology's Total Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -21.149
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Total Payout Ratio
Comparable Companies
ETST ASRT MRMD RMTI SCYX CPIX INCR SXTC RSCI INIS ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.